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ABSTRACT
Macrophage activation syndrome (MAS) 
is a serious and potentially fatal complica-
tion of various diseases, mainly systemic in-
flammatory connective tissue disorders, the 
most frequent being systemic juvenile idi-
opathic arthritis (sJIA). Its most important 
clinical and laboratory manifestations are 
non-remitting fever, hepatosplenomegaly, 
impaired liver function, cytopenia, hypoal-
buminemia, hypertriglyceridemia, hypofi-
brinogenemia and hyperferritinemia. The 
prognosis for the syndrome is often poor, 
so a prompt diagnosis and the appropriate 
medical treatment are critical for survival. 
We report a case of an 8-year-old boy who 
developed MAS as a complication of sJIA. 
The boy presented with liver insufficiency, 
impaired coagulation, encephalopathy and 
respiratory failure and was treated in in-
tensive care unit (ICU). He has achieved 
complete remission of the disease after ther-
apy with pulse doses of corticosteroids and 
ciclosporin.
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INTRODUCTION
MAS is a serious, potentially fatal compli-
cation of rheumatic diseases, which is seen 
most frequently in systemic juvenile idio-
pathic arthritis (SJIA) and in its adult equiv-
alent, adult-onset Still’s disease, although it 
is increasingly reported in other paediatric 
inflammatory disorders, namely juvenile 
systemic lupus erythematosus and Kawasaki 
disease. (1, 2) In recent years, this condition 
has also been observed in periodic fever 
syndromes. MAS may occur spontaneously, 
as a complication of active underlying dis-
ease, or may be triggered by an infection, 
a change in drug therapy or a toxic effect 
of a medication, including biologics. (1) 
Clinically, patients with MAS present with 
non-remitting high fever, pancytopenia, 
hepatosplenomegaly, hepatic dysfunction, 
encephalopathy, coagulation abnormalities 
and sharply increased levels of ferritin. The 
pathognomonic feature of the syndrome is 
seen on bone marrow examination, which 
reveals numerous morphologically benign 
macrophages exhibiting haemophagocytic 
activity (figure 1). Such cells may also be 
found in lymph nodes and spleen, but they 
may infiltrate almost any organ in the body 
and may account for many of the systemic 
features of the syndrome. As MAS bears 
a close resemblance to a group of histio-
cytic disorders collectively known as hae-
mophagocytic lymphohistiocytosis (HLH), 
it is currently classified among the second-
ary, or acquired, forms of HLH (3)
CASE REPORT
The patient is an 8-year-old boy diagnosed 
with sJIA in December 2012. He was treated 
by a paediatrician in a regional hospital with 
low doses of prednisone and methotrexate 
(MTX) with partially controlled disease. 
In August 2013 he presented with daily 
(quotidian) fever, pain and swelling of both 
knees and the left wrist with evanescent, 
salmon-colouredrash. Laboratory analy-
ses have shown increased parameters of 
inflammation, anaemia of chronic disease, 
and thrombocytosis with high ferritin level. 
In September 2014 he suddenly presented 
with mucocutaneous bleeding, seizures and 
breathing difficulties and was admitted to 
our hospital. The boy was unconscious dur-
ing examination (Glasgow coma score 4), 
hypotensive, had high grade fever, hemor-
rhagic skin rash, mucosal bleeding, tachy-
cardia, tachypnea, hepatosplenomegaly and 
axillar lymphadenopathy. He had repeating 
tonic-clonic seizures.
On examination the patient had anemia (Hb 
8.2 g/dL), trombocytopenia (26 × 10³/L), 
elevated serum lactate dehydrogenase 
(1670 U/L) and liver enzyme levels (aspar-
tate aminotransferase 268 U/L and alanine 
aminotransferase 356 U/L), prolonged pro-
thrombin time (1,9), reduced serum levels 
of fibrinogen (78 mg/dL), increased triglyc-
erides (455 mg/dL) and ferritin (4600 ng/
mL). 
He was admitted to the ICU, intubated, put 
on ventilatory support, received parenteral 
fluid replacement and inotropic agent. He 
received transfusion of fresh frozen plasma 
and thrombocyte concentrate that con-
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trolled the bleeding. Convulsions were 
stopped with midazolam. Bone marrow 
examination revealed haemophagocytosis 
(figure 1). Lumbar punction was in refer-
ence values. He was diagnosed with MAS 
and treated with 5 pulses of methylpred-
nisolone 30 mg/kg/day, followed by oral 
prednisone (PDN) 2 mg/kg/day and ciclo-
sporin (CSA) 5 mg/kg/day. MTX was sus-
pended.
The disease remitted after eight weeks. His 
last laboratory results showed the normali-
zation of ferritin (190 ng/mL), triglycer-
ides (64 mg/dL), haemoglobin (12.7 g/dL), 
fibrinogen (240 mg/mL), AST (23 U/L) 
and ALT (30 U/L). The patient is currently 
treated with PDN 5 mg/day and CSA 6 
mg/kg/day.
DISCUSSION
MAS is a life-threatening condition asso-
ciated with high mortality rates. Although 
the reported mortality rates for MAS reach 
20%, the clinical presentation of mac-
rophage activation syndrome (MAS) is 
generally acute and occasionally dramatic. 
(1 - 3) Typically, patients become acutely 
ill with the sudden onset of non-remitting 
high fever, profound depression in all 3 
blood cell lines (i.e. leukopenia, anaemia, 
and thrombocytopenia), hepatospleno-
megaly, lymphadenopathy, and elevated 
serum liver enzyme levels. MAS is overt 
in 10% of children with sJIA, but occurs 
subclinically in another 30-40%. It is im-
portant to emphasize that the diagno-
sis of MAS is often a challenge as it may 
mimic a flare of the underlying disease. 
Therefore,  it is difficult to distinguish 
sJIA disease flare from MAS. There are no 
validated criteria for the diagnosis of MAS. 
A 2014 retrospective analysis concluded 
that HLH-2004 guidelines are likely not 
appropriate for identification of MAS in 
children with sJIA. Ravelli et al. proposed 
diagnostic guidelines for MAS complicat-
ing sJIA, based on expert consensus. These 
preliminary MAS guidelines showed the 
strongest ability to identify MAS in sJIA. 
The diagnosis of macrophage activation 
syndrome requires the presence of any 2 or 
more of the following laboratory criteria or 
2 or more of the following clinical criteria 
(table 1). (4)
The treatment for MAS is based on corti-
costeroids and CSA. CSA has been proven 
as effective therapy in patients with severe 
disease and corticosteroid resistant. (5 - 7) 
That is why it was introduced early in the 
treatment. 
MAS can be triggered by an infection, a 
change in drug therapy or a toxic effect 
of a medication, including biologics. (8) 
We consider that the trigger for MAS in 
the case of our patient was the inadequate 
treatment by the paediatrician in the re-
gional hospital and unsatisfactory disease 
monitoring.
Figure 1: bone marrow aspirate showing 
macrophage with engulfed red blood cells
Table 1. Preliminary diagnostic guidelines 
for macrophage activation syndrome com-
plicating systemic juvenile idiopathic ar-
thritis
LABORATORY CRITERIA
o Decreased platelet count (< 262 x 109/L)
o Elevated aspartate aminotransferase levels 
(>59 U/L)
o Decreased WBC count (< 4 x 109/L)
o Hypofibrinogenemia (≤2.5 g/L)
CLINICAL CRITERIA
o CNS dysfunction (e.g. irritability, disorien-
tation, lethargy, headache, seizures, coma)
o Hemorrhages (e.g. purpura, easy bruising, 
mucosal bleeding)
o Hepatomegaly (≥3 cm below the costal 
margin)
HISTOPATHOLOGIC CRITERION
• Evidence of macrophage hemophago-
cytosis is found in the bone marrow 
aspirate sample. The demonstration of he-
mophagocytosis in bone marrow samples 
may be required in doubtful cases. 
CNS – central nervous system, WBC – 
white blood cell count
CONCLUSION
MAS is a serious complication of systemic 
rheumatic disorders, primarily sJIA, asso-
ciated with long-term morbidity and mor-
tality. The purpose of this case report is to 
motivate paediatricians for early recogni-
tion of the clinical manifestations of MAS. 
Early diagnosis and aggressive therapeutic 
approach are the critical points in MAS 
management and the ones capable of mod-
ifying patient’s outcome. 
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